Panitumumab: Phase III data

Top-line data from a double-blind, placebo-controlled, international Phase III trial (181) in 1,186 patients showed that Vectibix plus FOLFIRI chemotherapy met the co-primary endpoint of significantly improving PFS in patients with wild-type K-Ras vs. FOLFIRI alone. Vectibix plus FOLFIRI missed the co-primary endpoint of significantly improving OS in the same subset of patients vs. FOLFIRI alone. The addition of Vectibix had no positive or negative effect on PFS or OS in patients with tumors containing activating K-Ras mutations. ...